The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients
- PMID: 16729298
- DOI: 10.1002/hep.21176
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients
Abstract
Large databases of consecutive patients followed for sufficiently long periods are needed to establish the rates, chronology, and hierarchy of complications of cirrhosis as well as the importance of other potential causes of liver disease. In accordance with this goal, a cohort of patients with compensated cirrhosis due to hepatitis C virus (HCV) was followed for 17 years. Two hundred and fourteen HCV RNA-seropositive patients with Child-Pugh class A cirrhosis who had no previous clinical decompensation were prospectively recruited and followed up with periodic clinical and abdominal ultrasound examinations. During 114 months (range 1-199), hepatocellular carcinoma (HCC) developed in 68 (32%), ascites in 50 (23%), jaundice in 36 (17%), upper gastrointestinal bleeding in 13 (6%), and encephalopathy in 2 (1%), with annual incidence rates of 3.9%, 2.9%, 2.0%, 0.7%, and 0.1%, respectively. Clinical status remained unchanged in 154 (72%) and progressed to Child-Pugh class B in 45 (21%) and class C in 15 (7%). HCC was the main cause of death (44%) and the first complication to develop in 58 (27%) patients, followed by ascites in 29 (14%), jaundice in 20 (9%), and upper gastrointestinal bleeding in 3 (1%). The annual mortality rate was 4.0% per year and was higher in patients with other potential causes of liver disease than in those without them (5.7% vs. 3.6%; P = .04). In conclusion, hepatitis C-related cirrhosis is a slowly progressive disease that may be accelerated by other potential causes of liver disease. HCC was the first complication to develop and the dominant cause for increased mortality.
Similar articles
-
Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.Am J Gastroenterol. 2009 May;104(5):1147-58. doi: 10.1038/ajg.2009.31. Epub 2009 Apr 7. Am J Gastroenterol. 2009. PMID: 19352340
-
Natural history of compensated viral B and D cirrhosis.Rom J Gastroenterol. 2005 Dec;14(4):329-35. Rom J Gastroenterol. 2005. PMID: 16400347
-
Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.Clin Oncol (R Coll Radiol). 2007 Apr;19(3):197-203. doi: 10.1016/j.clon.2006.12.005. Epub 2007 Jan 18. Clin Oncol (R Coll Radiol). 2007. PMID: 17359907
-
Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Am J Gastroenterol. 2009 Jul;104(7):1802-29. doi: 10.1038/ajg.2009.191. Epub 2009 May 19. Am J Gastroenterol. 2009. PMID: 19455106 Review.
-
The natural history of hepatitis C virus infection.Saudi Med J. 2003 Jul;24 Suppl 2:S67-70. Saudi Med J. 2003. PMID: 12897903 Review.
Cited by
-
Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy.J Gastroenterol. 2024 Nov 15. doi: 10.1007/s00535-024-02174-z. Online ahead of print. J Gastroenterol. 2024. PMID: 39545995
-
Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management.BJC Rep. 2024 May 3;2(1):39. doi: 10.1038/s44276-024-00050-0. BJC Rep. 2024. PMID: 39516538 Free PMC article.
-
Diagnostic performance of Sonazoid-enhanced CEUS in identifying definitive hepatocellular carcinoma in cirrhotic patients according to KLCA-NCC 2022 and APASL 2017 guidelines.Insights Imaging. 2024 Oct 31;15(1):263. doi: 10.1186/s13244-024-01838-x. Insights Imaging. 2024. PMID: 39480596 Free PMC article.
-
Risk of Malignancy in Indeterminate Liver Nodules Among Patients with Cirrhosis: A Retrospective Cohort Study.J Gastrointest Cancer. 2024 Oct 16;56(1):1. doi: 10.1007/s12029-024-01122-7. J Gastrointest Cancer. 2024. PMID: 39414724 Free PMC article.
-
DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C.Sci Rep. 2024 Oct 10;14(1):23760. doi: 10.1038/s41598-024-75280-w. Sci Rep. 2024. PMID: 39390065 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical